INT99782

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.55
First Reported 2001
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 21
Total Number 23
Disease Relevance 18.40
Pain Relevance 6.50

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Cxcl10) extracellular space (Cxcl10) extracellular region (Cxcl10)
Anatomy Link Frequency
NK cell 3
endothelial cells 1
leukocytes 1
Th1 cell 1
epithelial cell 1
Cxcl10 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 467 100.00 Very High Very High Very High
cytokine 317 100.00 Very High Very High Very High
chemokine 205 99.24 Very High Very High Very High
interstitial cystitis 656 96.74 Very High Very High Very High
Paracetamol 5 93.28 High High
Inflammatory response 21 92.40 High High
Inflammatory mediators 18 88.16 High High
cva 18 70.64 Quite High
Multiple sclerosis 18 45.48 Quite Low
metalloproteinase 1 31.36 Quite Low
Disease Link Frequency Relevance Heat
INFLAMMATION 469 100.00 Very High Very High Very High
Cystitis 1120 99.88 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 18 99.20 Very High Very High Very High
Inflammatory Bowel Disease 124 98.92 Very High Very High Very High
Disease 291 98.84 Very High Very High Very High
Colitis 70 98.60 Very High Very High Very High
Interstitial Cystitis 656 96.74 Very High Very High Very High
Lichen Sclerosus Et Atrophicus 16 95.84 Very High Very High Very High
Infection 69 95.56 Very High Very High Very High
Oral Lichen Planus 16 94.56 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The ability of CXCL10 blockade to modulate local chemokines as well as Th1 cytokine mRNA expression and to facilitate the decline of serum levels of CXCL9 and CXCL10 is an indication of reduced local as well as systemic inflammation.
Negative_regulation (decline) of CXCL10 associated with chemokine, inflammation and cytokine
1) Confidence 0.55 Published 2008 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC2583981 Disease Relevance 0.75 Pain Relevance 0.36
Most importantly, our data show CXCL10 blockade partially attenuates these changes.


Spec (partially) Negative_regulation (blockade) of CXCL10
2) Confidence 0.55 Published 2008 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC2583981 Disease Relevance 0.36 Pain Relevance 0.09
Our results show that CXCL10 blockade does not affect the percentage of CD4+ T cells in the spleen of naïve mice, but inhibition of CXCL10 in CYP-treated mice with cystitis lead to an increase in the percentage of T helper splenocytes.
Negative_regulation (inhibition) of CXCL10 in spleen associated with cystitis
3) Confidence 0.55 Published 2008 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC2583981 Disease Relevance 0.75 Pain Relevance 0.33
Neutralization of CXCR2 during IP-10 therapy resulted in an abrogation of the hepatoprotective effect of IP-10.
Negative_regulation (abrogation) of IP-10
4) Confidence 0.43 Published 2001 Journal J. Immunol. Section Abstract Doc Link 11739529 Disease Relevance 0.22 Pain Relevance 0.43
Despite the reduction of serum CXCL9 and CXCL10 levels following anti-CXCL10 Ab treatment(s) of mice given CYP, it remained uncertain whether CXCL10 blockade would improve the pathology of cystitis.
Negative_regulation (reduction) of CXCL10 associated with cystitis
5) Confidence 0.41 Published 2008 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC2583981 Disease Relevance 0.97 Pain Relevance 0.23
Indeed, CXCL10 inhibition might prove useful in other diseases.
Negative_regulation (inhibition) of CXCL10 associated with disease
6) Confidence 0.41 Published 2008 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC2583981 Disease Relevance 1.52 Pain Relevance 0.23
Thus, the decline in inflammatory cytokines levels might be a reflection of reduced inflammatory state and Th1 cell-mediated responses afforded by CXCL10 blockade.
Negative_regulation (blockade) of CXCL10 in Th1 cell associated with inflammation and cytokine
7) Confidence 0.41 Published 2008 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC2583981 Disease Relevance 1.54 Pain Relevance 0.54
The ability of CXCL10 blockade to modulate local chemokines as well as Th1 cytokine mRNA expression and to facilitate the decline of serum levels of CXCL9 and CXCL10 is an indication of reduced local as well as systemic inflammation.
Negative_regulation (blockade) of CXCL10 associated with chemokine, inflammation and cytokine
8) Confidence 0.41 Published 2008 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC2583981 Disease Relevance 0.80 Pain Relevance 0.41
Together, these results indicate that CXCL10 blockade modulates the number of systemic and mucosal NK cell subsets that are altered during CYP-induced cystitis.


Negative_regulation (blockade) of CXCL10 in NK cell associated with cystitis
9) Confidence 0.41 Published 2008 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC2583981 Disease Relevance 1.36 Pain Relevance 0.66
However, increases in serum CXCL10 (and CXCL9) concentrations were significantly reduced following CXCL10 blockade in mice that received CYP.
Negative_regulation (blockade) of CXCL10
10) Confidence 0.41 Published 2008 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC2583981 Disease Relevance 0.95 Pain Relevance 0.23
CXCL10 blockade protects mice from cyclophosphamide-induced cystitis

Background

Negative_regulation (blockade) of CXCL10 associated with cystitis
11) Confidence 0.41 Published 2008 Journal J Immune Based Ther Vaccines Section Title Doc Link PMC2583981 Disease Relevance 0.57 Pain Relevance 0.35
is a potent inducer of CXCL10 expression by endothelial cells [60]; this inflammatory cytokine was negatively modulated by CXCL10 blockade during CYP-induced cystitis.
Negative_regulation (blockade) of CXCL10 in endothelial cells associated with inflammation, cystitis and cytokine
12) Confidence 0.41 Published 2008 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC2583981 Disease Relevance 1.60 Pain Relevance 0.43
While NK cell subsets have not been demonstrated to play a profound role in IC or in CYP-induced cystitis, this study shows that NK and NKT cells were associated with cystitis in mice following CYP challenge, which was partially resolved by CXCL10 blockade.
Negative_regulation (blockade) of CXCL10 in NK cell associated with cystitis and interstitial cystitis
13) Confidence 0.41 Published 2008 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC2583981 Disease Relevance 1.01 Pain Relevance 0.51
However, CYP treatment significantly increased the percentage of urinary bladder CD4+ T cells to 50.5%, but CXCL10 blockade of CYP-treated mice decreased this percentage to 34.2%.
Negative_regulation (blockade) of CXCL10 in T cells
14) Confidence 0.41 Published 2008 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC2583981 Disease Relevance 0.24 Pain Relevance 0
Splenic NK cells were unchanged during cystitis, but CXCL10 blockade dramatically reduced the number of splenic and iliac lymph node NK cells that were increased during this disease.
Negative_regulation (blockade) of CXCL10 in NK cells associated with cystitis and disease
15) Confidence 0.41 Published 2008 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC2583981 Disease Relevance 1.23 Pain Relevance 0.54
Antibody (Ab)-mediated inhibition of the most abundant serum CXCR3 ligand, CXCL10, in mice decreased the local production of CXCR3 ligands as well as Th1 cytokines expressed by local leukocytes, and lowered corresponding serum levels to reduce the severity of CYP-induced cystitis.
Negative_regulation (inhibition) of CXCL10 in leukocytes associated with cystitis and cytokine
16) Confidence 0.41 Published 2008 Journal J Immune Based Ther Vaccines Section Abstract Doc Link PMC2583981 Disease Relevance 0.49 Pain Relevance 0.29
The gene array analysis in the present study detected greater than three-fold suppression of STAT1 and CXCL10 mRNA by 10 ?
Negative_regulation (suppression) of CXCL10
17) Confidence 0.39 Published 2010 Journal BMC Chem Biol Section Body Doc Link PMC2881005 Disease Relevance 0.30 Pain Relevance 0.08
Blockade of CXCL10 ameliorated murine AIDS and acute colitis by inhibiting cell trafficking as well as inhibiting cell proliferation while supporting crypt epithelial cell survival [56,57].
Negative_regulation (Blockade) of CXCL10 in epithelial cell associated with colitis and acquired immune deficiency syndrome or hiv infection
18) Confidence 0.35 Published 2008 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC2583981 Disease Relevance 1.35 Pain Relevance 0.17
As demonstrated in Figure 2, the top networks identified by IPA at 6 hours after pneumonectomy are associated with cell-cell signaling (including up-regulation of Ceacam1 and ItgaV - Figure 2A), and inhibition of inflammatory cell migration (down-regulation of the pro-inflammatory cytokines Cxcl1 and Cxcl10, as well as Nf??
Negative_regulation (regulation) of Cxcl10 associated with inflammation and cytokine
19) Confidence 0.31 Published 2009 Journal Respir Res Section Body Doc Link PMC2770038 Disease Relevance 0.47 Pain Relevance 0.24
Since STAT1 regulates iNOS [38] and CXCL10 [30,41], suppression of pSTAT1 by PEO likely contributes to the downstream inhibition of iNOS and CXCL10.
Negative_regulation (inhibition) of CXCL10
20) Confidence 0.29 Published 2010 Journal BMC Chem Biol Section Body Doc Link PMC2881005 Disease Relevance 0.32 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox